目錄:MedChemExpress LLC>>信號通路>> Parsaclisib hydrochloride | MCE
CAS | 1995889-48-9 | 純度 | 98.74% |
---|---|---|---|
分子量 | 469.34 | 分子式 | C??H??Cl?FN?O? |
供貨周期 | 現(xiàn)貨 | 規(guī)格 | 10 mg |
貨號 | HY-109068A | 應(yīng)用領(lǐng)域 | 醫(yī)療衛(wèi)生,化工,生物產(chǎn)業(yè),制藥 |
MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào),我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)。
產(chǎn)品活性:Parsaclisib hydrochloride (INCB050465 hydrochloride) 是一種有效,選擇性和具有口服活性的 PI3Kδ 抑制劑,IC50 值為 1 nM。Parsaclisib hydrochloride 相對于其他 PI3K I 類同工型的選擇性約為 20000 倍。Parsaclisib hydrochloride 可用于研究復(fù)發(fā)或難治性 B 細(xì)胞惡性腫瘤。
研究領(lǐng)域:PI3K/Akt/mTOR
作用靶點(diǎn):PI3K
In Vitro: Parsaclisib (0.1-3000 nM; 4 d) inhibits proliferation of MCL and DLBCL cell lines.
Parsaclisib (0.1-1000 nM; 2 h) inhibits anti-IgM-induced pAKT (Ser473) in the Ramos Burkitt’s lymphoma cell line, with an IC50 of 1 nM.
Parsaclisib inhibits the proliferation of human, dog, rat, and mouse primary B cells after activation of these receptors, with IC50s ranging from 0.2 to 1.7 nM.
In Vivo: Parsaclisib (10 mg/kg; oral gavage twice daily for 7-19 days) inhibits tumor growth in the BALB/c mice bearing the A20 murine lymphoma cells.
Parsaclisib (0.1-10 mg/kg; p.o. twice daily) slows Pfeiffer xenograft tumor growth in a dose-dependent manner. And Parsaclisib was well tolerated.
Parsaclisib (0.5-1 mg/kg; a single p.o.) inhibits pAKT (Ser473) in Pfeiffer subcutaneous mouse xenograft models.
相關(guān)產(chǎn)品:Drug Repurposing Compound Library Plus | Clinical Compound Library Plus | Bioactive Compound Library Plus | Kinase Inhibitor Library | PI3K/Akt/mTOR Compound Library | Stem Cell Signaling Compound Library | Anti-Cancer Compound Library | Clinical Compound Library | Autophagy Compound Library | Anti-Aging Compound Library | Drug Repurposing Compound Library | Differentiation Inducing Compound Library | Oxygen Sensing Compound Library | Glycolysis Compound Library | Cytoskeleton Compound Library | Orally Active Compound Library | Anti-Breast Cancer Compound Library | Anti-Lung Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Anti-Blood Cancer Compound Library | Anti-Cancer Metabolism Compound Library | Anti-Obesity Compound Library | Angiogenesis-Related Compound Library | Glucose Metabolism Compound Library | Anti-Liver Cancer Compound Library | Rare Diseases Drug Library | Anti-Colorectal Cancer Compound Library | Anti-Prostate Cancer Compound Library | Anti-Pulmonary Fibrosis Compound Library | Cancer Stem Cells Compound Library | Heterocyclic Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | Umbralisib hydrochloride | PI3K-IN-22 | Rigosertib sodium | PI3Kδ/γ-IN-2 | PI3kδ inhibitor 1 | GSK2292767 | PI3K-IN-28 | PI3K/mTOR Inhibitor-13 | Disitertide diammonium | 1,3-Dicaffeoylquinic acid | Quercetin dihydrate | PI3Kγ inhibitor 4 | PI-103 Hydrochloride | Hirsutenone | Sophocarpine monohydrate | Heterophyllin B | IC-87114 | Phosphatidylinositol 4,5-bisphosphate | Chaetominine | SF2523 | Flupentixol | GNE-490 | AZD-7648 | Serabelisib | PI3K-IN-38 | PI3Kα-IN-5 | Boc-L-cyclobutylglycine | NIBR-17 | PI3K/HDAC-IN-1
品牌介紹:
• MCE (MedChemExpress) 擁有200 多種*僅有化合物庫,我們致力于為*科研客戶提供前沿的高品質(zhì)小分子活性化合物;
• 50,000 多種高選擇性抑制劑、激動(dòng)劑涉及各熱門信號通路及疾病領(lǐng);
• 產(chǎn)品種類涵蓋各種重組蛋白,多肽,常用試劑盒 ,更有 PROTAC、ADC 等特色產(chǎn)品,廣泛應(yīng)用于新藥研發(fā)、生命科學(xué)等科研項(xiàng)目;
• 提供虛擬篩選,離子通道篩選,代謝組學(xué)分析檢測分析,藥物篩選等專業(yè)技術(shù)服務(wù);
• 設(shè)有專業(yè)的實(shí)驗(yàn)中心和嚴(yán)格的質(zhì)控、驗(yàn)證體系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項(xiàng)質(zhì)檢報(bào)告,確保產(chǎn)品的高純度、高品質(zhì);
• 產(chǎn)品的生物活性多經(jīng)各國客戶實(shí)驗(yàn)驗(yàn)證;
• Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果;
• 專業(yè)團(tuán)隊(duì)跟蹤最新的制藥及生命科學(xué)研究進(jìn)展,為您提供*新的活性化合物;
• 與世界各大制藥公司及著名科研機(jī)構(gòu)建立了長期的合作。
(空格分隔,最多3個(gè),單個(gè)標(biāo)簽最多10個(gè)字符)